Business
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024
CAMBRIDGE, Mass., March 31, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update following the filing of its 10-K on Friday March 28, 2025 which reported financial results for the fourth quarter and year ended December 31, 2024.
About this update from Enveric Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/d43607420448f6b52bf4cabb09652539"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6OPLxY0T9aXKRywM_HTVgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d43607420448f6b52bf4cabb09652539","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/b9mkQycwqJQ9wrkGC8EteQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/d43607420448f6b52bf4cabb09652539","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Product Development Highlights:","length":31,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Advanced pre-IND and research activities including confirmation of oral bioavailability and significant brain exposure for EB-003, a novel potential first-in-class neuroplastogenic molecule designed to treat severe mental health disorders","length":238,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced positive pharmacology and preclinical safety data for EB-003 including targeting of serotonergic receptors, supporting the potential of the neuroplastogenic therapeutic effect","length":185,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Presented data highlighting development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop and 7th Neuropsychiatric Drug Summit","length":148,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Broadened pipeline of potential non-hallucinatory molecules with new U.S. patent for EVM401 Series mescaline derivative compounds","length":129,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":700,"olType":false},{"type":"text","content":"Corporate and Business Development Highlights:","length":46,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Conducted business development campaign with multiple classes of promising novel drug candidates ","length":96,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Executed out-licensing deal of patented topical product to Aries Science & Technology for development in radiation dermatit...